FVC decline | No FVC decline | p-value | FEV1 decline | No FEV1 decline | p-value | |
Subjects | 28 | 119 | 29 | 118 | ||
Age years | 61.79±10.42 | 60.79±8.81 | 0.651 | 63.55±9.50 | 60.20±8.91 | 0.063 |
BMI kg·m−2 | 23.65±3.53 | 22.73±2.71 | 0.187 | 23.51±3.02 | 22.76±2.68 | 0.326 |
Brinkman index cigarette-years | 737.6±409.8 | 754.4±416.4 | 0.866 | 863.3±387.8 | 725.9±417.1 | 0.028* |
mean BP mmHg | 100.8±10.4 | 97.8±13.5 | 0.128 | 99.25±11.61 | 98.19±13.38 | 0.436 |
HbA1c % | 5.03±0.36 | 5.14±0.57 | 0.288 | 5.09±0.36 | 5.13±0.57 | 0.963 |
ALT U·L−1 | 26.64±12.81 | 26.75±14.99 | 0.782 | 28.00±13.85 | 26.42±14.77 | 0.377 |
sCr mg·dL−1 | 0.696±0.096 | 0.759±0.114 | 0.007* | 0.728±0.107 | 0.752±0.115 | 0.3 |
Triglycerides mg·dL−1 | 148.57±97.66 | 139.29±86.68 | 0.632 | 132.58±67.66 | 143.14±93.15 | 0.851 |
Total cholesterol mg·dL−1 | 192.39±29.34 | 194.40±30.07 | 0.805 | 194.86±30.47 | 193.80±29.81 | 0.748 |
Homocysteine μM | 12.4 (11.1–14.3) | 11.9 (10.0–14.0) | 0.148 | 13.8 (11.7–18.4) | 11.0 (9.6–12.8) | 0.001* |
Log homocysteine | 1.09±0.11 | 1.07±0.12 | 0.148 | 1.13±0.11 | 1.06±0.01 | 0.001* |
FVC % pred | ||||||
First visit | 97.79±15.57 | 97.88±13.83 | 0.668 | 95.70±16.06 | 98.39±13.62 | 0.668 |
Second visit | 90.76±15.40 | 104.55±13.58 | <0.0001* | 92.09±16.17 | 104.34±13.61 | <0.0001* |
FEV1 % pred | ||||||
First visit | 92.63±18.44 | 97.49±16.04 | 0.236 | 90.71±20.94 | 98.01± 15.08 | 0.158 |
Second visit | 84.01±19.23 | 98.73±16.35 | 0.0001* | 78.44±21.07 | 100.23±14.01 | <0.0001* |
FEV1/FVC % | ||||||
First visit | 74.27±7.68 | 77.95±8.47 | 0.039* | 73.78±10.12 | 78.11±7.77 | 0.019* |
Second visit | 71.99±10.64 | 73.27±9.02 | 0.657 | 65.86±12.86 | 74.79±7.28 | <0.0001* |
Data are presented as n, mean±sd or median (interquartile range), unless otherwise stated. Data on homocysteine levels were not available for four of the 147 subjects. Brinkman index data were not available for 19 subjects due to the lack of information on precise smoking habits. Differences in Brinkman index and homocysteine levels between subjects who did, or did not, show a decline in pulmonary function were evaluated by the Mann–Whitney U-test. Differences in all other variables were evaluated by t-test. BMI: body mass index; BP: blood pressure; Hb: haemoglobin; ALT: alanine aminotransferase; sCr: serum creatinine; FVC: forced vital capacity; % pred: % predicted; FEV1: forced expiratory volume in 1 s.